David A. Siegel Athira Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 253,300 shares of ATHA stock, worth $93,721. This represents 0.0% of its overall portfolio holdings.
Number of Shares
253,300
Previous 337,600
24.97%
Holding current value
$93,721
Previous $151,000
1.32%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ATHA
# of Institutions
62Shares Held
18.8MCall Options Held
17.2KPut Options Held
800-
Perceptive Advisors LLC New York, NY5.4MShares$2 Million0.11% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.78MShares$1.03 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.56MShares$575,9600.0% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$552,3330.05% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$552,3330.87% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $14M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...